5-ethylspiro[3,4,4a,5,7,7a-hexahydro-1H-furo[3,4-b]pyridine-2,1'-cyclopentane]

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 5-ethylspiro[3,4,4a,5,7,7a-hexahydro-1H-furo[3,4-b]pyridine-2,1'-cyclopentane]
• 化学式: C₁₃H₂₃NO
• 分子量: 209.33
• InChiKey: MPAFMWIBEHBEKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2017044434A1

  公开（公告）日：2017-03-16

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新颖的杂环芳基化合物，其药用盐和制剂。它们在预防、管理、治疗或减轻蛋白激酶介导的疾病的严重程度方面具有用处。该发明还提供了包括这些化合物的药用组合物以及使用这些组合物治疗蛋白激酶介导的疾病的方法。
• HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20140234254A1

  公开（公告）日：2014-08-21

  The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

  本发明提供了杂环芳基衍生物及其药用可接受的盐和制剂，用于调节蛋白激酶活性，特别是磷脂酰肌醇3-激酶（PI3激酶）和mTOR，并调节细胞内和/或细胞间信号活动，如增殖、分化、凋亡、迁移和侵袭。该发明还提供了包括这些化合物的药用可接受组合物以及在治疗哺乳动物，特别是人类的高增殖性疾病中使用这些组合物的方法。
• SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20160229837A1

  公开（公告）日：2016-08-11

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新颖的杂环芳基化合物，药用可接受的盐及其制剂，用于预防、管理、治疗或减轻蛋白激酶介导的疾病的严重程度。本发明还提供了包含这些化合物的药用可接受的组合物，以及使用这些组合物治疗蛋白激酶介导的疾病的方法。
• BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20170044140A1

  公开（公告）日：2017-02-16

  Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

  本文提供了一种式(I)的桥接的融合物，或其立体异构体、互变异构体、N-氧化物、水合物、溶剂合物、代谢物、药用盐或其前药，可用于治疗丙型肝炎病毒（HCV）感染或丙型肝炎疾病。此外，本文还提供了含有这些化合物的药物组合物以及使用这些化合物或药物组合物治疗HCV感染或丙型肝炎的方法。
• BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20150299219A1

  公开（公告）日：2015-10-22

  The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.

  本发明提供了取代的双环吡唑酮化合物，用于抑制或调节受体酪氨酸激酶的活性，特别是Axl、Mer、c-Met和Ron。本发明还提供了包含上述化合物的制药组合物，以及使用上述化合物或制药组合物预防、治疗或减轻患者的增殖性疾病的方法。